HealthQuill Myelofibrosis
Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss firm access to a key drug for treating blood cancer.
Drugs Health Pharma

Novartis to buy MorphoSys for $2.9 billion to expand cancer portfolio

HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.

Read More
X